Study at a glance
How does vitamin D travel through the blood?
Forms of vitamin D travel mainly attached to proteins or fat-carrying particles. Vitamin D-binding protein carries most of the longer-lasting 25-hydroxyvitamin D, the form measured in the usual blood test. Other carriers also contribute.
Does vitamin D from skin enter the same transport system as vitamin D taken by mouth?
The routes differ at first. A small human study found skin-made vitamin D3 mainly attached to vitamin D-binding protein. Vitamin D2 taken by mouth also travelled with fat-carrying particles. This transport finding does not establish that one source has better health effects.
Why does attachment to proteins matter?
Being attached to a carrier affects how long forms of vitamin D remain in blood and how quickly they reach other parts of the body. It helps maintain a reserve in the blood, but it does not explain every tissue’s access to vitamin D.
Read the full article below ↓What plasma transport has to accomplish
Vitamin D compounds are hydrophobic molecules, so movement through an aqueous circulation depends heavily on carrier proteins and lipoprotein particles. The important physiological point is that “vitamin D transport” is not one uniform process. Carrier partitioning changes with the molecular form being transported and, for parent vitamin D, with how it entered the circulation. That distinction affects how quickly material leaves plasma, reaches the liver, persists in the circulating reservoir and becomes available for later metabolism.
DBP dominates the long-lived circulating system
Human tracer studies established an early kinetic distinction between parent vitamin D and its 25-hydroxylated metabolite. Vitamin D3 disappeared relatively rapidly from plasma, whereas the polar metabolite with the properties of 25-hydroxyvitamin D persisted much longer. Fractionation experiments placed most of the circulating radioactivity associated with the metabolite in a specific high-density protein fraction rather than in the major lipoprotein fractions. This work helped establish vitamin D binding protein (DBP) as the principal high-affinity plasma carrier for hydroxylated vitamin D metabolites.
That dominance should not be converted into the stronger claim that DBP is the only carrier. Albumin binds a smaller fraction of circulating hydroxylated metabolites, and parent vitamin D can have a materially different early transport history.
Route of entry changes parent-vitamin-D transport
Direct human experiments comparing cutaneously generated vitamin D3 with orally administered vitamin D showed that source matters. After ultraviolet-B exposure, newly synthesized vitamin D3 appeared in plasma almost exclusively in association with DBP. By contrast, orally administered vitamin D was distributed substantially between DBP and chylomicron/lipoprotein fractions during the post-absorptive period.
That difference is physiologically coherent. Vitamin D absorbed from the intestine enters the circulation through lipid-transport machinery, whereas vitamin D released from skin does not pass through the same intestinal chylomicron phase. The two routes therefore converge on the vitamin-D transport system from different starting points rather than producing identical immediate plasma partitioning.
Binding changes kinetics, not just solubility
DBP should not be viewed as inert packaging. Strong carrier binding expands the circulating reservoir and slows loss of vitamin D metabolites from plasma. Experimental absence of DBP produces extremely low circulating 25-hydroxyvitamin D concentrations and more rapid clearance, yet biological vitamin-D action is not abolished. That combination is important: DBP is a major determinant of circulating persistence and buffering, but it is not an absolute prerequisite for every biological action of vitamin D metabolites.
This reservoir function also helps explain why total circulating concentration and immediate tissue access are related but not interchangeable concepts. A large protein-bound pool can support persistence while only a small fraction is unbound at any moment. The distinction is developed further in Free vs Total Vitamin D Explained.
What the evidence does and does not establish
The strongest synthesis is therefore conditional rather than absolute. DBP is the dominant high-affinity carrier for most circulating hydroxylated vitamin D metabolites. Albumin contributes a smaller binding pool. Parent vitamin D can additionally travel in chylomicrons and other lipoprotein fractions, especially after oral absorption. Cutaneously synthesized vitamin D3 enters the plasma transport system differently and is carried predominantly by DBP.
These carrier systems alter residence time, reservoir size and delivery kinetics. They do not by themselves tell us how every tissue acquires vitamin D metabolites from blood. That requires a separate tissue-delivery question within the wider story of vitamin D in the body, because some tissues can access carrier-bound substrate through specialised uptake mechanisms while others may depend more strongly on the free fraction.
Primary evidence and publication details
Smith JE, Goodman DS. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest. 1971;50:2159-2167.
Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest. 1993;91:2552-2555.
Safadi FF et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest. 1999;103:239-251.
Related reading
Synthesis of Deuterium-Labeled Vitamin D Metabolites as Internal Standards for LC-MS Analysis
However, other D3 metabolites, such as 20-hydroxyvitamin D3 and lactone D3, also show interesting biological activities and stable isotope-labeled derivatives are required for LC-MS/MS analysis of their concentrations in serum.
Original paper ↗Read more →Potential roles of vitamin D binding protein in attenuating liver injury in sepsis
The current study examined the relationship between serum VDBP level and liver injury in sepsis patients, as well as in a mouse model for sepsis and in cultured liver epithelial cell line exposed to lipopolysaccharide (LPS).
Original paper ↗Read more →The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases
Vitamin D (calciferol) is a fat-soluble vitamin that has a significant role in phospho-calcium metabolism, maintaining normal calcium levels and bone health development.
Original paper ↗Read more →Vitamin D Binding Protein Structure and Transport Role: Evidence Synthesis
Explore how vitamin D binding protein carries vitamin D metabolites, maintains circulating stores and supports specialised uptake pathways in the body.
Read more →25-Hydroxyvitamin D and Vitamin D Binding Protein Levels in Patients With Primary Hyperparathyroidism Before and After Parathyroidectomy
To evaluate vitamin D binding protein and free 25-hydroxyvitamin D [25(OH)D] levels in healthy controls compared to primary hyperparathyroidism (PHPT) patients, and to examine PHPT before and after surgery.
Original paper ↗Read more →Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2 supplementation
We aimed to investigate the changes of total 25(OH)D, 25(OH)D3 and 25(OH)D2 in a Thai cohort, according to type of vitamin D supplement (vitamin D3 or D2) and DBP genotype, after receiving vitamin D3 or D2 for 3 months.
Original paper ↗Read more →Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein
Serum 25-hydroxyvitamin D [25(OH)D] is often deficient (.
Original paper ↗Read more →Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: A cross-sectional study
All participants were genotyped for polymorphisms rs2282679, rs4588, and rs7041.
Original paper ↗Read more →Maternal and Neonatal Vitamin D Binding Protein Polymorphisms and 25-Hydroxyvitamin D Cutoffs as Determinants of Neonatal Birth Anthropometry
Our aim was to assess the combined effect of maternal and neonatal VDBP polymorphism heterogeneity in conjunction with different maternal and neonatal 25(OH)D cutoffs on the neonatal anthropometric profile at birth.
Original paper ↗Read more →The GC2 haplotype of the vitamin D binding protein is a risk factor for a low plasma 25-hydroxyvitamin D concentration in a Han Chinese population
Compared with VDI, VDS, or both, VDD showed higher plasma concentrations of fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides in males (P 0.05).
Original paper ↗Read more →The Role of Vitamin D Binding Protein, Total and Free 25-Hydroxyvitamin D in Diabetes
Vitamin D is important for bone health, but may also have extra-skeletal effects.
Original paper ↗Read more →Vitamin D-Binding Protein, Bioavailable, and Free 25(OH)D, and Mortality: A Systematic Review and Meta-Analysis
Introduction: Observational studies reported inverse associations between serum total 25-hydroxyvitamin D (25(OH)D) concentrations and mortality.
Original paper ↗Read more →Vitamin D Binding Protein Genotype Is Associated with Serum 25-Hydroxyvitamin D and PTH Concentrations, as Well as Bone Health in Children and Adolescents in Finland
We examined the role of GC genotypes in S-25(OH)D status and BMD in 231 Finnish children and adolescents aged 7−19 yr.
Original paper ↗Read more →Vitamin D Binding Protein Impact on 25-Hydroxyvitamin D Levels under Different Physiologic and Pathologic Conditions
The aim of this review is to assess DBP concentration in different physiological and pathophysiological conditions.
Original paper ↗Read more →Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis
Blacks have different dominant polymorphisms in the vitamin D-binding protein (DBP) gene that result in higher bioavailable vitamin D than whites.
Original paper ↗Read more →Vitamin D Binding Protein Explained
A physiology-first explanation of vitamin D binding protein, detailing how it buffers circulation, regulates delivery, and shapes cellular and system-level vitamin D availability.
Read more →Association of longitudinal serum 25-hydroxyvitamin D trajectories with subsequent liver stiffness increase in patients with early-onset type 2 diabetes and metabolic dysfunction-associated steatotic liver disease
We evaluated the associations of longitudinal 25(OH)D trajectories with subsequent liver stiffness measurement (LSM) increases in patients with early-onset type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.
Original paper ↗Read more →Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients
The objective of this study is to retrospectively probe the association between the 25-hydroxyvitamin D (25-(OH)D) and NAFLD in type 2 diabetic patients.
Original paper ↗Read more →Disrupted Vitamin D Metabolism in Hepatocellular Carcinoma: Free and Bioavailable 25(OH)D as Novel Biomarkers of Hepatic Reserve and Clinical Risk
Correlations with Child: Pugh score, Barcelona Clinic Liver Cancer (BCLC) stage, and disease aetiology were evaluated.
Original paper ↗Read more →Liver Graft Pathology and Low Serum 25-Hydroxyvitamin D after Living Donor Liver Transplantation
Aims: We conducted this study to explore the interplay between VDR and CYP2R1 in liver graft and compared our findings with the pathological interpretation of serum 25(OH)D concentration.
Original paper ↗Read more →Low Serum 25-Hydroxyvitamin D Levels Are Related to Frailty and Sarcopenia in Patients with Chronic Liver Disease
This study aimed at exploring the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and frailty or sarcopenia in 231 patients with CLD.
Original paper ↗Read more →Original sources
The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma
Published in J Clin Invest (1971).
Publication details
Smith JE, Goodman DS. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest. 1971;50:2159-2167.
Human plasma transport of vitamin D after its endogenous synthesis
Published in J Clin Invest (1993).
Publication details
Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest. 1993;91:2552-2555.
Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein
Published in J Clin Invest (1999).
Publication details
Safadi FF et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest. 1999;103:239-251.